Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of differentially expressed between MCF7 and TAMR after ATF2 silencing

ABSTRACT: The goal of this study was to identify genes that were differentially regulated by ATF2 in TAMR cells (tamoxifen-resistant MCF7 derivatives) when compared to the tamoxifen-sensitive MCF7.

ORGANISM(S): Homo sapiens

PROVIDER: GSE145548 | GEO | 2020/11/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of differentially expressed between MCF7 and TAMR after ATF2 silencing

Project description:Identification of differentially expressed between MCF7 and TAMR after ATF2 silencing

| PRJNA607536 | ENA

Regulation of gene expression by ATF2 in mouse melanocytes

Project description:primary melanocytes from WT and ATF2 mutant (transcriptionally inactive) mice expressing the mutant N-ras transgene were prepared and assessed for changes in gene expression when maintained under normoxia and hypoxia growth conditions. 12 mouse melanocyte samples were analyzed during normoxia and hypoxia, with different ATF2 genotypes. The pivotal samples are represented as duplicates. Treatment of tamoxifen was used to induce recombination and expression of the mutant ATF2 (inducible Cre). Doxycyclin was used to induce expression of mutant N-Ras transgene.

2010-08-30 | E-GEOD-23860 | biostudies-arrayexpress

CHIP-SEQ of FOXA1 in parental MCF7 cells and tamoxifen resistant MCF7 cells

Project description:ChIP sequencing of FOXA1 in MCF7 cells and tamoxifen resistant MCF7 cells

2016-11-01 | GSE75201 | GEO

mRNA expressiom profiling of breast cancer cell line MCF-7 and its endocrine-resistant lines

Project description:To explore the mechanism of endocrine resistance development in estrogen receptor positive breast cancer, transcriptome analysis of MCF-7 and its endocrine resistant derivatives, including tamoxifen resistant (TAMR) sub-lines and long-term estrogen deprivation (LTED) sub-lines, were performed using microarray.

2023-06-14 | GSE234546 | GEO

Gene expression analysis in tamoxifen resistant ER+ breast cancer cell lines

Project description:To elucidate the molecular mechanisms of tamoxifen resistance in breast cancer, we performed gene array analysis and identified 366 genes with altered expression in four unique tamoxifen resistant (TamR) cell lines vs the parental tamoxifen sensitive MCF7/S0.5 cell line. Most of these genes were funcationally linked to cell proliferation, death and control gene expression, and include FYN, PRKCA, ITPR1, DPYD, DACH1, LYN, GBP1 and PRLR. Treatment with FYN specific small interfering RNA or a SRC family kinase inhibitor reduced cell growth of TamR cell lines while exerting no significant effect on MCF7/S0.5 cells. Moreover, overexpression of FYN in parental tamoxifen-sensitive MCF7/S0.5 cells resulted in reduced sensitivity to tamoxifen, demonstrating growth and survival promoting function of FYN in MCF7 cells. FYN knockdown in TamR cells led to reduced phosphorylation of 14-3-3 and CDc 25A, suggesting that FYN, by activation of of important cell cycle-associated proteins, may overcome the anti-proliferative effects of tamoxifen. Evaluation of the subcellular localization of FYN in primary breast tumors from two cohorts of endocrine-treated ER+ breast cancer patients, one with advanced disease (N = 47) and the other with early disease (N = 76), showed that in the former, plasma membrane-associated FYN expression strongly correlated with longer progression-free survival (P<0.0002). Similarly, in early breast cancer patients, membrane-associated expression of FYN in the primary breast tumor was significantly associated with increased metastasis-free (P<0.04) and overall (P<0.004) survival independent of tumor size, grade or lymph node status. Our results indicate that FYN has an important role in tamoxifen resistance, and its subcellular localization in breast tumor cells may be an important novel biomarker of response to endocrine therapy in breast cancer.

2016-04-10 | GSE67916 | GEO

Transcriptomic profiles of MCF7-derived tamoxifen resistant cell lines

Project description:We report mRNA profiles of human breast cancer cell lines, MCF7 parental, and MCF7-derived tamoxifen resistant cell lines MCF7-TR1 and MCF7-TR2.

2023-10-25 | GSE241654 | GEO

Transcriptionally inactive ATF2 variant drives melanomagenesis [Seq]

Project description:Characterized by striking metastatic propensity and chemoresistance, melanoma is among the most lethal cutaneous malignancies. The transcription factor ATF2 was shown to elicit oncogenic activities in melanoma, and its inhibition attenuates melanoma development. Here, a mouse model engineered to express a transcriptionally inactive form of Atf2 (Atf2?8,9) was found to be sufficient to induce nevi formation and, when crossed with BrafV600E animals, to promote melanoma development. The cross of Atf2?8,9 with BrafV600E;Pten-/- mice augmented pigmentation, tumorigenicity, and metastasis. Similar to mouse Atf2?8,9, the human ATF2 splice variant 5 enhanced growth and migration capacity of cultured melanoma and immortalized melanocytes. Induced Melan-A, CXCL9, S100A8, CCR7 expression, seen in Atf2?8,9-driven tumors associate with their enhanced pigmentation, immune infiltration and propensity to metastasize. Notably, elevated ATF2SV5 expression in melanoma specimens coincided with poor prognosis. The gain-of-function activity elicited by the truncated ATF2 form offers unexpected insight into mechanisms underlying melanoma development and progression.

2016-04-29 | GSE79917 | GEO

Transcriptionally inactive ATF2 variant drives melanomagenesis [Array]

2016-05-02 | GSE81013 | GEO

Differential expression profiling of the TamR cells following AR knockdown

Project description:The androgen receptor (AR) has emerged as a candidate target for the treatment of breast cancer. In this study, we sought to characterize the functional consequences of AR knockdown using a siRNA-mediated approach in a tamoxifen-resistant (TamR) derivative of MCF7 breast cancer cell line.

2018-06-05 | GSE115270 | GEO

Alternative splicing of ALDOA determines tamoxifen resistance in breast cancer

Project description:Via analyzing the landscape of AS events in primary and relapse breast tumors from patients receiving tamoxifen-based therapy, it was revealed that exon skipping (ES) of exon 7.2 in 5’UTR of ALDOA pre-mRNA is associated with tamoxifen resistance. Therefore, RNA Sequencing is performed for MCF7-TAMR cells infected with ctr or ALDOA shRNAs to identify the molecular mechanism of ALDOA in mediating TAM resistance in breast cancer cells.

2024-02-26 | GSE245500 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data